Clinical Trials Details

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

IRB Protocol Number

S2303

Clinical Trial Categories

• Gastric Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: 

A randomized trial adding Nivolumab to usual treatment for adults with advanced stomach or esophageal cancer who have previously received therapy.

• Participants must not have received more than one prior line of systemic therapy
• Participants must have PD-L1 CPS (Combined Positive Score) ≥ 1
• Participants must have disease progression or intolerance to frontline standard of care (SOC) chemotherapy plus either nivolumab, pembrolizumab or any other PD-1 or PD-L1